NCT07031336

Photon-counting CT in Chest Imaging

Recruiting now NA Last updated 28 January 2026

What this trial tests

NA trial testing Photon-counting CT in COPD (Chronic Obstructive Pulmonary Disease) in 40 participants. Currently enrolling.

Timeline

14 November 2025

Primary endpoint
12 May 2026

12 May 2026

Quick facts

Lead sponsor	Duke University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	40
Start date	14 November 2025
Primary completion	12 May 2026
Estimated completion	12 May 2026
Sites	1 location across United States

Drugs / interventions tested

• Photon-counting CT
• Energy-integrating CT

Conditions studied

• COPD (Chronic Obstructive Pulmonary Disease) — all drugs for COPD (Chronic Obstructive Pulmonary Disease) →

Sponsor

Duke University

Who can join

Eligibility, any sex, with COPD (Chronic Obstructive Pulmonary Disease). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Purpose and objective: This project aims to evaluate photon-counting computed tomography (PCCT) quantitative accuracy using COPDGene subjects. The goal is to establish acquisition protocols for PCCT scans with proper post-processing (e.g., reconstruction parameters and harmonization techniques) that enable reproducible measurements of emphysema metrics (e.g., Perc15, LAA-950, HU accuracy) and airways (Pi10, WA%) in the lungs.

Study activities and population group: The study will recruit subjects from a current study at Duke (COPDGene Phase 4, Pro00113442). Here are the aims:

* The research team will request consent from participants to acquire PCCT scans at their Phase 4 COPDGene visit. Scans will be performed using a PCCT-specific protocol.
* Reconstruct the PCCT images with multiple post-acquisition parameter settings. Apply harmonization techniques that are recently developed by the investigators of this study.

Data analysis:

* Identify the reconstruction and harmonization conditions that enable reproducible measurements of emphysema metrics (perc15, LAA-950, HU accuracy) and airways (Pi10, WA%), when compared to the counterpart EICT scans.
* Demonstrate the non-inferiority and potentially improved capabilities of PCCT scans in cross-sectional and longitudinal studies.

Risk/safety issues:

The participants are asked to get an additional CT scan with a PCCT scanner at their COPDGene Phase 4 visit. This additional CT scan will be done using an inspiratory chest protocol with a total of 3 mGy (\~1.5 mSv) radiation dose. This is roughly equivalent of 6 month of background radiation. Women who are pregnant will not have a chest CT scan done until they are confirmed to be not pregnant.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.